Guardant Health price target lowered to $60 from $65 at Canaccord

Canaccord lowered the firm’s price target on Guardant Health to $60 from $65 and keeps a Buy rating on the shares. The analyst believes the shares are undervalued and the initial outlook is entirely achievable, with potential upside from reimbursement later in 2023.